Assignee
NAT CANCER CENTER JAPAN
JP·5 granted patents·3 pending applications·4 citations·filing 2017–2023
Top patents by PatentIndex Score
8 records- 0179US11311626B2Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugateNAT CANCER CENTER JAPAN·Filed 2018·Granted Apr 26, 2022·3 cites·11 claims
- 0274US11377504B2Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including sameNAT CANCER CENTER JAPAN·Filed 2018·Granted Jul 5, 2022·1 cites·4 claims
- 0370US2024148893A1Anti-tmem-180 antibody, anticancer agent, and test method for cancerNAT CANCER CENTER JAPAN·Filed 2023·Application pending·0 cites
- 0466US2023257708A1Novel t-cell receptorNAT CANCER CENTER JAPAN·Filed 2023·Application pending·0 cites
- 0558US11603519B2T-cell receptorNAT CANCER CENTER JAPAN·Filed 2018·Granted Mar 14, 2023·0 cites·17 claims
- 0654US11633499B2Anti-TMEM-180 antibody, anticancer drug and cancer testing methodNAT CANCER CENTER JAPAN·Filed 2017·Granted Apr 25, 2023·0 cites·2 claims
- 0743US2020041511A1Effector type regulatory t cell detecting method, effector type regulatory t cell analyzing device, effector type regulatory t cell analyzing system, and non-transitory storage mediumNAT CANCER CENTER JAPAN·Filed 2019·Application pending·0 cites
- 0839US11192956B2Antibody binding to TMEM132A, anticancer agent, and cancer test methodNAT CANCER CENTER JAPAN·Filed 2017·Granted Dec 7, 2021·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when NAT CANCER CENTER JAPAN files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →